TY - JOUR
T1 - Should high-dose N-acetylcysteine be given in cases of massive paracetamol overdoses
T2 - A narrative review
AU - Erichsen, Philip Ahle
AU - Dalhoff, Kim
AU - Andersen, Michael Asger
N1 - © 2024 The Author(s). Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
PY - 2024/9
Y1 - 2024/9
N2 - N-acetylcysteine (NAC) is regarded as an effective treatment of paracetamol overdoses. However, in cases of "massive" paracetamol overdoses, recent studies indicate that patients may not be sufficiently treated with the standard dose of NAC (300 mg/kg over 20-21 h). The subject is further complicated because "massive overdoses" and "high-risk" are defined differently; some studies use the ingested amount (e.g., >40 g), and some studies use blood concentrations of paracetamol and transaminases. This narrative review investigates whether high-dose NAC significantly decreases the risk of hepatotoxicity in patients with massive paracetamol overdoses. Three observational studies were analysed; one study with 373 patients found no significant difference (odds ratio [OR]: 1.27, 95% confidence interval [CI]: 0.49-3.29). One study with 79 patients found a significant difference (OR: 0.27, 95% CI: 0.08-0.94). The third study with 89 patients found a significant difference in hepatoxicity between the groups (p = 0.043). There are no solid evidence to support that treatment with high-dose NAC significantly reduces the rate of hepatotoxicity in patients presenting with massive paracetamol overdoses. Differences in inclusion criteria in the included studies make the studies incomparable. This paper shows that standardized inclusion is needed to determine whether a high-dose NAC regimen should be included in clinical practice.
AB - N-acetylcysteine (NAC) is regarded as an effective treatment of paracetamol overdoses. However, in cases of "massive" paracetamol overdoses, recent studies indicate that patients may not be sufficiently treated with the standard dose of NAC (300 mg/kg over 20-21 h). The subject is further complicated because "massive overdoses" and "high-risk" are defined differently; some studies use the ingested amount (e.g., >40 g), and some studies use blood concentrations of paracetamol and transaminases. This narrative review investigates whether high-dose NAC significantly decreases the risk of hepatotoxicity in patients with massive paracetamol overdoses. Three observational studies were analysed; one study with 373 patients found no significant difference (odds ratio [OR]: 1.27, 95% confidence interval [CI]: 0.49-3.29). One study with 79 patients found a significant difference (OR: 0.27, 95% CI: 0.08-0.94). The third study with 89 patients found a significant difference in hepatoxicity between the groups (p = 0.043). There are no solid evidence to support that treatment with high-dose NAC significantly reduces the rate of hepatotoxicity in patients presenting with massive paracetamol overdoses. Differences in inclusion criteria in the included studies make the studies incomparable. This paper shows that standardized inclusion is needed to determine whether a high-dose NAC regimen should be included in clinical practice.
KW - Acetylcysteine/administration & dosage
KW - Humans
KW - Acetaminophen/poisoning
KW - Drug Overdose/drug therapy
KW - Chemical and Drug Induced Liver Injury/etiology
KW - Analgesics, Non-Narcotic/poisoning
KW - Antidotes/administration & dosage
KW - Dose-Response Relationship, Drug
KW - Observational Studies as Topic
UR - http://www.scopus.com/inward/record.url?scp=85198535568&partnerID=8YFLogxK
U2 - 10.1111/bcpt.14051
DO - 10.1111/bcpt.14051
M3 - Review
C2 - 39004668
SN - 1742-7843
VL - 135
SP - 285
EP - 294
JO - Basic & clinical pharmacology & toxicology
JF - Basic & clinical pharmacology & toxicology
IS - 3
ER -